10 Best Cheapest Stocks To Invest In Right Now

With college graduation season upon us, it’s again time to take a look at which majors garner the most pay.

For all of the jobs in the Top 30, starting pay was up over last year. Engineering and science occupations continued their stranglehold on the top third of the rankings. For the record, still coming in dead last is Child and Family Studies with a starting salary of $30,300 and a mid-career salary (15 years in) of $37,200.

In 2012, we looked at which degrees were paying the most. This year, as we did in 2013, we drilled down into specific majors using data from payscale.com. Payscale lists 129 majors on its site.

(Check out: 15 Cheapest Colleges With Best Job Value on ThinkAdvisor)

The rankings below are based on data collected from 1,000 universities and include graduates with bachelor’s degrees only. The universities surveyed include 88% of U.S. schools with an enrollment of more than 5,000.

Take a look at the 30 Best Paying College Majors for 2014:

Top 5 Communications Equipment Stocks To Buy Right Now: Raptor Pharmaceutical Corp.(RPTP)

Raptor Pharmaceuticals Corp. operates as a biotechnology company in the United States. The company is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. Its clinical stage development products include DR Cysteamine, which is in phase IIb for the treatment of cystinosis; phase IIa for the non-alcoholic steatohepatitis; and phase II for the treatment of Huntington?s disease. Raptor?s clinical-stage products also include Convivia that is in Phase IIa stage for the potential management of acetaldehyde toxicity due to alcohol consumption; and Tezampanel and NGX 426, which completed phase I stage for the treatment of migraine and pain. Its preclinical product candidates comprise HepTide for the treatment of Hepatocellular Carcinoma and Hepatitis; WntTide for the treatment of breast cancer; NeuroTrans for the treatmen t of neurodegenerative diseases; and Tezampanel and NGX 426 for the treatment of Thrombosis and Spasticity Disorder. Raptor Pharmaceuticals Corp. is headquartered in Novato, California.

Advisors' Opinion:

• [By Sean Williams]

  Raptor Pharmaceuticals (NASDAQ: RPTP  ) also gave shareholders something to cheer about when, on Tuesday, the company announced that the Food and Drug Administration had granted Procysbi, its nephropathic cystinosis drug, U.S. orphan drug status. Although FDA-approved drugs are protected by patent for a period of 20 years, the U.S. orphan drug status will keep biosimilar competition from competing against Raptor's Procysbi through April 30, 2020. In addition, on Friday Procysbi received a positive opinion from the European Medicine Agency's panel that the drug be recommended for approval in the EU. However, I'd caution calmer heads prevail here as the total market for the drug is only about 2,000 people worldwide and peak sales estimates in the U.S. are a mere $60 million.

• [By Roberto Pedone]

  One biotechnology player that's starting to trend within range of triggering a big breakout trade is Raptor Pharmaceuticals (RPTP), which has a pipeline that includes both candidates from its proprietary drug targeting platforms and in-licensed and acquired product candidates. This stock is in play with the bulls so far in 2013, with shares up sharply by 151%.

  >>5 Hated Earnings Stocks You Should Love

  If you take a look at the chart for Raptor Pharmaceuticals, you'll notice that stock has been uptrending strong for the last six months, with shares soaring higher from its low of $5.50 to its recent high of $15.29 a share. During that uptrend, shares of RPTP have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of RPTP within range of triggering a big breakout trade.

  Traders should now look for long-biased trades in RPTP if it manages to break out above some near-term overhead resistance levels at $14.99 a share to its 52-week high at $15.29 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 844,332 shares. If that breakout triggers soon, then RPTP will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $18 to $20 a share, or even north of $20 a share.

  Traders can look to buy RPTP off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $13.69 a share or at $13 a share. One can also buy RPTP off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By Sean Williams]

  Veloci-Raptor time?
  First up is Raptor Pharmaceuticals (NASDAQ: RPTP  ) with Procysbi (previously known as RP-103), its oral delayed and extended-release medication to treat nephropathic cystinosis. In trials, Procysbi proved to be non-inferior to the only other FDA-approved treatment for nephropathic cystinosis, known as Cystagon from Mylan (NASDAQ: MYL  ) .

10 Best Cheapest Stocks To Invest In Right Now: MTS Systems Corporation(MTSC)

MTS Systems Corporation supplies test systems and industrial position sensors in the Americas, Europe, and Asia. The company?s Test segment provides testing solutions, including road simulators for durability simulation; tire performance and rolling resistance measurement systems; moving road-plane systems and balances use for aerodynamics measurements in wind tunnels; systems for the physical characterization of materials, such as ceramics, composites, and steel; systems to test durability and performance of implants, prostheses, and other medical and dental materials and devices. This segment also offers products, systems, and software to perform static and fatigue testing of aircraft and space vehicles; systems for structural engineering, including high force static and dynamic testing; and seismic simulation tables to test the designs of structures and set building codes. In addition, it provides various accessories and spare parts, as well as installation, calibratio n, maintenance, training, and consulting services. This segment serves automobile, truck, motorcycle, motorsports vehicle, construction equipment, agricultural equipment, rail, and off-road vehicle manufacturers and their suppliers, as well as power generation, aerospace, bio-medical, wind energy, structural engineering, and petroleum industries. The company?s Sensors segment manufactures products utilizing magnetostriction technology for manufacturers of mobile equipment, plastic injection molding machines, and wood product processing equipment, as well as to steel mill, fluid power, oil and gas, medical, and alternative energy industries. It also offers products to measure fluid displacement for customers in the process industries. The company sells its products through direct sales organization, and independent representatives and distributors, as well as through the Internet and catalogs. MTS Systems Corporation was founded in 1966 and is headquartered in Eden Prairie, Minnesota.

Advisors' Opinion:

• [By Brian Pacampara]

  Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, road simulator specialist MTS Systems (NASDAQ: MTSC  ) has earned a coveted five-star ranking.

10 Best Cheapest Stocks To Invest In Right Now: Midway Gold Corporation(MDW)

Midway Gold Corp., an exploration stage company, engages in the acquisition, exploration, and development of mineral properties in North America. Its principal properties include the Spring Valley, Midway, Pan, and Gold Rock gold and silver mineral properties located in Nevada; and the Golden Eagle gold mineral property located in Washington. The company was formerly known as Red Emerald Resource Corp. and changed its name to Midway Gold Corp. in July 2002. Midway Gold Corp. was founded in 1996 and is headquartered in Englewood, Colorado.

Advisors' Opinion:

• [By Lisa Levin]

  Midway Gold (NYSE: MDW) shares fell 3.90% to reach a new 52-week low of $0.74. Midway Gold's trailing-twelve-month ROA is -11.16%.

  Posted-In: 52-Week LowsNews Movers & Shakers Intraday Update Markets

10 Best Cheapest Stocks To Invest In Right Now: Golden Minerals Co (AUM)

Golden Minerals Company (Golden Minerals), incorporated March 6, 2009, is a mining company. The Company owns and operates the Velardena and Chicago precious metals mining operations (the Velardena Operations) in the State of Durango, Mexico, the El Quevar advanced exploration property in the province of Salta, Argentina, and a diversified portfolio of precious metals and other mineral exploration properties located in the regions of Mexico and South America.

Velardena Operations

The Velardena Operations consists of two underground mines and two processing plants within the Velardena mining district, which is located in the municipality of Cuencame, in the northeast quadrant of the State of Durango, Mexico, approximately 65 kilometers southwest of the city of Torreon, Coahuila and approximately 140 kilometers northeast of the city of Durango, the capital of the State of Durango. Of the two underground mines consisting the Velardena Operations, the Velardena mine includes three different vein systems, including the Santa Juana, San Juanes and San Mateo systems. The second mine, the Chicago mine, is a producing mine located on the Chicago property approximately two kilometers south of the Velardena property.

The Company owns a 300 ton-per-day flotation sulfide mill situated near the town of Velardena. The mill has fully operational lead, zinc, and pyrite flotation circuits which produce lead, zinc and pyrite concentrates from the sulfide ore. The Company also own a conventional 550 ton-per-day cyanide leach oxide mill with a Merrill Crowe precipitation circuit and new installed flotation circuit, which is located adjacent to its Chicago mine. The mill is used to process oxide and mixed sulfide/oxide material from the Velardena Operations.

El Quevar

The Company's El Quevar silver project is located in the San Antonio de los Cobres municipality, Salta Province, in the altiplano region of northwestern Argentina, approximately 300 kilometers by! road northwest of the city of Salta, the capital city of the province. The El Quevar project is located near Nevado Peak with altitudes at the concessions ranging from 3,800 to 6,130 meters above sea level. The El Quevar project is consists of 32 exploitation concessions. The Company holds 31 of the concessions directly, and the Company controls the Nevado I concession, located approximately four kilometers from the Yaxtche target.

Zacatecas (Mexico)

The Zacatecas Mining District is located in the central part of Mexico, in the Faja de Plata mineral belt. The Company's Zacatecas project surrounds the municipalities of Zacatecas, Veta Grande, Guadalupe, Panuco, and Morelos in the state of Zacatecas, Mexico. The Company owns approximately 195 concessions totaling approximately 8,600 hectares in the Zacatecas project.

San Diego (Mexico)

The San Diego property, located in the State of Durango, Mexico, is situated approximately nine kilometers northeast of the Velardena property and contains the La Cruz-La Rata and El Trovador mines as well as a number of other shallower shafts which were sunk on narrower veins such as the Cantarranas, Montanez and El Jal. During the year ended December 31, 2012, a Phase VI drilling program was completed, which included five drill holes totaling 5,500 meters.

Advisors' Opinion:

• [By Joshi Madhavi]

  The company gets its revenues from two types of fees: management fees which are linked to the assets under management (AUM) and performance fees which can be quite volatile. Over the last five years AUM have increased by around 4% per annum from the low at the end of 2008. However, revenues have decreased by around 7% per annum. Performance fees have held up okay since 2008, but management fees have taken a big hit. Since revenues are dependent on the average AUM over the whole year, let�� look at revenues from 2009 ��they have grown by around 6.5% per annum in this case. Institutional clients are more sticky and stable compared to retail, but the company has not managed to increase AUM from this source substantially over the last five years.

10 Best Cheapest Stocks To Invest In Right Now: Renaissance Oil Corp (ROE)

Renaissance Oil Corp, formerly San Antonio Ventures Inc., is developing a diversified shale and mature fields portfolio for development in Mexico and Spain. The Company is partnered with Grupo SAMCA, a diverse industrial with operations in energy, mining, industrial minerals, agriculture, environmental and various other business lines in Spain. Advisors' Opinion:

• [By Holly LaFon]

  Question: What is your view on Travelers (TRV)�� competitive advantage? How troubling is the huge fixed-income portion of their investment portfolio (in relation to future inflation)? How much do you like Jay Fishman? I really like the fact they are aggressively repurchasing shares and the fact that it is trading at book value, which I estimate to earn around 13% (ROE).

• [By Holly LaFon]

  Investing in small or micro cap funds will be more volatile and loss of principal could be greater than investing in large cap or more diversified funds.Investing in foreign securities, especially in frontier and emerging markets, entails special risks, such as currency fluctuations and political uncertainties, which are described in more detail in the prospectus.For the period ended March 31, 2014, the average annual total returns of the Wasatch International Growth (Trades, Portfolio) Fund for the one-, five- and ten-year periods were 12.71%, 28.72%, and 10.73%, and the returns for the MSCI AC World Ex-U.S.A. Small Cap Index were 16.28%, 21.18%, and 9.31%. Expense ratio: Gross 1.57% / Net 1.57%.Recent stock market performance has caused atypical short-term returns for some asset classes,which may not continue in the future. Fund performance may be subject to substantial short-term changes due to market volatility.Data shows past performance, which is not indicative of future performance. Current performance may be lower or higher than the data quoted. To obtain the most recent month-end performance data available, please click on the ��erformance��tab of the individual fund under the ��ur Funds��section. The Advisor may absorb certain Fund expenses, without which total return would have been lower. Investment returns and principal value will fluctuate and shares, when redeemed, may be worth more or less than their original cost.Wasatch Funds will deduct a 2.00% redemption proceeds fee on Fund shares held 60 days or less. Performance data does not reflect the deduction of fees, including sales charges, or the taxes you would pay on fund distributions or the redemption of fund shares. Fees and taxes, if reflected, would reduce the performance quoted. Wasatch does not charge any sales fees. For more complete information including charges, risks and expenses, read the prospectus carefully.Wasatch Funds are subject to risks, including loss of principal.Over

• [By ovenerio]

  In this article, let麓s see one of the most important financial ratios applying to stockholders, the best measure of performance for a firm's management: the Return on Equity (ROE), and we are going to analyze it in the case of Oracle Corporation (ORCL), the leading provider of enterprise technology solutions, offering software, services and hardware.ROE is calculated as net income applicable to common shares divided by the average book value of common equity: ROE = Net Income / Av. Book ValueA higher ROE is viewed as a positive aspect for the company, but the reason behind it should be examine. From the equation above, we can see that if book value is decreasing more rapidly than net income, the ratio will increase, but this is not good for the firm.Dupont AnalysisThis approach can be used to analyze the ROE. With some algebra we can break down ROE into a function of different ratios. Firstly, we are going to consider the original approach:Original Dupont Equation: Three-Part DupontTaking the ROE equation: ROE = net income / shareholder's equity and multiplying ROE by (revenue / revenue), and rearranging terms we get:ROE = (net income / revenue) * (revenue / shareholder's equity)We now have ROE broken into two parts, the first is net profit margin, and the second is the equity turnover ratio. Now we can expand this by multiplying these terms by (assets / assets), and rearranging we end up with the three-step DuPont equation.ROE = (Net Income / Revenue) * (Revenue / Assets) * (Assets / Shareholder's Equity)This equation for ROE breaks it into three widely used and studied components:ROE = (Net profit margin)* (Asset Turnover) * (Leverage ratio)The first term is what we called previously net profit margin, the second term is asset turnover and the third tem is a financial leverage ratio. If we have a low ROE, one of the following must be true:The firm has a poor profit marginThe firm has a poor asset turnoverThe firm has a little leverageROE (%) 3 StepMay-05May-0

• [By Michael Robinson]

  Separate the signal from the noise: To create real wealth, you have to ignore Wall Street's hype machine and focus on firms with excellent fundamentals. And Jazz certainly has a great foundation. The company has operating margins of 41% and a return on stockholders' equity (ROE) of 31%.

10 Best Cheapest Stocks To Invest In Right Now: Research in Motion Limited(RIMM)

Research In Motion Limited (RIM) designs, manufactures, and markets wireless solutions for the worldwide mobile communications market. The company, through the development of integrated hardware, software, and services, provides platforms and solutions for seamless access to time-sensitive information, including email, phone, short messaging service, and Internet and Intranet-based applications and browsing. Its products and services principally comprise the BlackBerry wireless platform, the RIM Wireless Handheld product line, software development tools, and other software and hardware. The company?s BlackBerry smartphones use wireless, push-based technology that delivers data to mobile users? business and consumer applications. Its BlackBerry smartphone portfolio includes BlackBerry Bold series, the BlackBerry Torch, BlackBerry Curve series, the BlackBerry Style, BlackBerry Storm series, the BlackBerry Tour, BlackBerry Pearl series, and the BlackBerry PlayBook tablet. T he company?s BlackBerry enterprise solutions comprise BlackBerry enterprise server, BlackBerry enterprise server express, BlackBerry mobile voice system, and hosted BlackBerry services. Its technology also enables third party developers and manufacturers to enhance their products and services through software development kits, wireless connectivity to data, and third-party support programs. In addition, the company offers BlackBerry technical support services, non-warranty repairs, and nonrecurring engineering services. Further, it provides BlackBerry App World that offers BlackBerry smartphone users an electronic catalogue that aids in the discovery and download/purchase of applications directly from their BlackBerry smartphone. The company markets and sells its BlackBerry wireless solutions primarily through global wireless communications carriers, and third party distribution channels. Research In Motion Limited was founded in 1984 and is headquartered in Waterloo, Canad a.

Advisors' Opinion:

• [By Trustamind]

  Technology is disruptive. It changes everyone�� daily life. But it also may cause unpleasant financial consequences to investors. Technology brings dramatic economic growth which is, unfortunately, less predictable. In Buffett�� own words when asked in the interview if he would buy other tech companies: �� look at everything but most things I decide I can't figure out their future.��For some examples, just look at Research In Motion (RIMM) versus Apple (AAPL), Yahoo! (YHOO) versus Google (GOOG), and Kodak versus all the other digital camera makers. The last one is especially ironic because it is Kodak that invented the digital camera in the first place.

• [By Matthew Indyke and Brian Zen]

  Klarman said the following to investors in his Baupost letter earlier this year: ��ur disciplined risk aversion throughout 2011 enabled us to avoid dangerous temptations and remain focused on investments in our areas of strength and competitive advantage.��Competitive advantage comes down to two questions. Can the company raise prices for their products while maintaining sales in a competitive environment? Can it continue to retain customers as the business undergoes operational and technological changes? One aspect for investors to keep in mind is that of technological change, a constant threat to industries like retail stores and mobile communications. Best Buy (BBY) used to be the go-to place where customers could shop for electronic appliances but internet retail took that away. RIM (RIMM) used to be a model company that produced phones for email on-the-go but competitors like Apple (AAPL) and Google (GOOG) upped the ante and took away the value of RIM�� products. These kinds of circumstances show that keeping up with trends on a regular basis is a vital part of bottom-up investing.

• [By Holly LaFon]

  If an idea doubles within a year, the contestant will win more. This month, GuruFocus is awarding author Jean-Francois Nobert (Ecotycoon) $1,000 for his idea, Research In Motion (RIMM), which doubled since he submitted in July.

10 Best Cheapest Stocks To Invest In Right Now: BioMarin Pharmaceutical Inc.(BMRN)

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and rest of the world. The company?s commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used for the treatment of mucopolysaccharidosis (MPS) VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; and Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease. It develops GALNS, an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder; PEG-PAL, an enzyme substitution therapy that is under Phase II clinical trial to treat PKU; BMN-673, a Phase I/II clinical trial product for the treatment of cancer; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trials for Pompe disease, a glycogen storage disorder; and BMN-111, a peptide therapeutic that is under Phase I clinical trial for the treatment of achondroplasia. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation for the manufacture of Aldurazyme; and an agreement with Merck Serono S.A. for the further development and commercialization of Kuvan and other products containing 6R-BH4 and PEG-PAL for PKU. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in Novato, California.

Advisors' Opinion:

• [By Monica Gerson]

  BioMarin Pharmaceutical (NASDAQ: BMRN) shares moved up 1.48% to $78.64. The volume of BioMarin Pharmaceutical shares traded was 966% higher than normal. BioMarin shares jumped on Roche Holding (OTC: RHHBY) takeover report..

• [By MONEYMORNING.COM]

  There is no crystal ball that's 100% accurate when experimental drugs are concerned, but here are some telling questions that can narrow your search.

  Questions to Answer Before You Buy In Does the drug fulfill an unmet need?
  
  Alexion Pharmaceuticals Inc.'s (Nasdaq: ALXN) Soliris (eculizumab) is the only drug approved to treat paroxysmal nocturnal hemoglobinuria (PNH), an extremely rare, lethal blood disorder. It is also the only therapy approved to treat atypical hemolytic uremic syndrome (aHUS), a genetic condition that can result in sudden and progressive damage to vital organs, leading to stroke, heart attack, and kidney failure. Five years ago, ALXN shares were selling for about $18.50. They recently hit a high of $180.51 - thanks to Soliris, and Soliris alone. Is it a "breakthrough" drug?
  
  A "Breakthrough Therapy" (BT) is actually a designation awarded by the FDA for a drug that "...is intended alone or in combination with one or more other drugs to treat a serious or life-threatening disease or condition and [has] preliminary clinical evidence [that] indicates the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development." In 2012, the FDA granted Roche/Genetech's Gasyva a BT designation and then approved it for marketing in 2013. It treats chronic lymphocytic leukemia (CLL) and is expected to be a big blockbuster - as are the other three breakthrough therapies that were approved last year. Can its market produce blockbuster income?
  
  This can mean a huge market, such as patients with high cholesterol - think Pfizer Inc.'s (NYSE: PFE) Lipitor (atorvastatin calcium), the bestselling drug of all time - or a small market that will pay for highly priced orphan drugs for rare diseases. BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a company that specializes in the
• [By George Budwell]

  Will BioMarin be the next orphan drugmaker to be bought out?
  Over the last decade, BioMarin Pharmaceutical (NASDAQ: BMRN  ) has become one of the top orphan drug specialists, making it a frequent visitor to the buyout rumor mill. Roche (NASDAQOTH: RHHBY  ) was previously named as an interested party, but the company's CEO squashed that rumor, saying BioMarin was too expensive.

• [By Sean Williams]

  BioMarin Pharmaceuticals (NASDAQ: BMRN  )
  BioMarin might as well be considered a long lost sibling of Alexion, since they are both focused on developing rare orphan drugs which have practically no competition and hefty annual price tags, often in six-figures. However, whereas Alexion is profitable, BioMarin has some "'splaining to do," as Desi Arnaz used to say. Estimates in the upcoming quarter call for sales growth of just 8% to $134 million with losses expected to widen to $0.29 per share. Naglazyme's 1% sales increase last quarter didn't impress at all, so it'll need Aldurazyme to really step up if it hopes to maintain its frothy valuation.

Top 10 Medical Companies For 2014

The so-called fundamentals, frankly, don't really matter for Entest BioMedical Inc. (OTCMKTS:ENTB) or Gevo, Inc. (NASDAQ:GEVO). Oh, both GEVO and ENTB are generating sales, but both are consistently taking losses. That's ok though, as for both companies right now, profits aren't really the point - it's the pipeline that matters.

Then again, though both Gevo, Inc. and Entest BioMedical Inc. are on the same proverbial expectations-boat doesn't mean neither are trade-worthy. As a matter of fact, both are quite trade-worthy explicitly because they are nothing more than trading instruments, being pushed around by speculation and psychology, which is - amazingly enough - sometimes easier to handicap than actual "value". Thing is, though both ENTB and GEVO are dropping big hints as to the budding direction of their bigger undertow, these two stocks are most definitely not pointed in the same direction.

Top 10 China Companies To Own For 2015: Euromedis Groupe SA (EMG)

Euromedis Groupe SA is a France-based company that specializes in the design, manufacture, distribution, rental and export of medical and surgical equipment and products, and services for medical home care for hospitals, clinics, retirement homes, physicians, pharmacies, and individuals. The Company's product portfolio include products, such as syringes and needles; surgical equipment, such as catheters, instrumentation and compresses; gloves; hygiene products, comprising disposable clothing, masks and paper towel products, and pharmaceutical equipment, offering cotton wool and thermometers. Euromedis Groupe SA exports its products to Europe and Africa. Advisors' Opinion:

• [By Inyoung Hwang]

  Man Group Plc (EMG) advanced 3.6 percent to 85.85 pence. The world�� largest publicly traded hedge-fund manager posted its first quarterly net inflows in two years as clients added money to funds at its GLG Partners unit. Sales of Man Group�� funds totaled $4.1 billion in the third quarter, exceeding $3.4 billion of redemptions.

• [By Sofia Horta e Costa]

  Commodity producers increased as base metals rallied, with BHP Billiton Ltd. (BHP), the largest mining company, climbing 3.7 percent. Man Group (EMG) Plc soared 13 percent on a plan to redeem debt. Royal Bank of Scotland Group Plc dropped by the most in two months after Britain�� biggest state-owned lender reported operating profit that fell short of analysts��estimates.

Top 10 Medical Companies For 2014: Imprimis Pharmaceuticals Inc (IMMY)

Imprimis Pharmaceuticals Inc. is a specialty pharmaceutical company developing non-invasive, topically delivered products. The Company�� Transdel cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier. Ketotransdel, the Company�� lead pain product, utilizes the Transdel platform technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), through the skin directly into the underlying tissues where the drug exerts its anti-inflammatory and analgesic effects. Ketotransdel consists of a transdermal formulation of ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), and its Transdel drug delivery system and is being developed for the treatment of acute pain. In July 2013, it acquired intellectual property for IPI-120 from Buderer Drug Company.

Ketotransdel penetrates the skin barrier to reach the targeted underlying tissues where it exerts its localized anti-inflammatory and analgesic effect. Transdel is the Company�� transdermal cream drug delivery platform. It consists of a cream that enables transdermal penetration of drugs avoiding first pass metabolism by the liver and minimizing systemic exposure. The Transdel drug delivery system facilitates the effective dissolution and delivery of a drug across the skin barrier to reach targeted underlying tissues.

Advisors' Opinion:

• [By John Udovich]

  So far this year, Rexahn Pharmaceuticals, Inc (NYSEMKT: RNN), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and Arrowhead Research Corp (NASDAQ: ARWR) are up 186.3%, 157.2% and 142.5%, respectively, since the start of the year���making them the best performing small cap biotech stocks for 2014. But given their lackluster performance over the past few years, what is the secret behind their phenomenal 2014 rise and will they keep rising? For starters, none of these small caps have really produced anything in the way of blockbuster news:

• [By John Udovich]

  The start of 2014 shows that biotech is still a hot area with the sector along with small cap biotech stocks like AMAG Pharmaceuticals, Inc (NASDAQ: AMAG), Mast Therapeutics Inc (NYSEMKT: MSTX), Cell Therapeutics Inc (NASDAQ: CTIC), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and TNI BioTech (OTCMKTS: TNIB) producing news or returns�plus Auspex Pharmaceuticals (NASDAQ: ASPX), Cara Therapeutics (NASDAQ: CARA), Egalet (NASDAQ: EGLT), Flexion Therapeutics (NASDAQ: FLXN) and Ultragenyx Pharmaceutical (NASDAQ: RARE) are among the (many�� planned biotech IPOs that have recently been announced publicly:

Top 10 Medical Companies For 2014: ImmunoCellular Therapeutics Ltd (IMUC)

ImmunoCellular Therapeutics, Ltd., incorporated on March 20, 1987, is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. Immunotherapy is an approach to treat cancer in which a patient�� own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies. The Company�� products include ICT-107, ICT-140, ICT-120, ICT-109 and DIAAD. ICT-107, the pipeline product, is a Phase II therapeutic dendritic cell (DC) vaccine for the treatment of glioblastoma multiforme (GBM), the common and lethal type of brain cancer. ICT-107 is designed to activate a patient�� immune system to target six different tumor-associated antigens. In February 2012, it acquired a world-wide license from the University of Pennsylvania and The John Hopkins University (JHU).

The Company in addition to ICT-107, is also developing other therapeutic DC vaccines: ICT-140 for ovarian cancer and ICT-121 for recurrent GBM. ICT-140 targets seven tumor-associated antigens expressed on ovarian cancer cells. ICT-107 is a DC vaccine that targets six different tumor-associated antigens that are found on patients��tumor cells; four of the six antigens are expressed on CSCs. The therapeutic vaccine is used subsequent to conventional therapy or concomitantly with chemotherapy in patients with newly diagnosed GBM. ICT-140 is a DC vaccine that targets seven different ovarian cancer antigens. ICT-121 is a DC vaccine that targets CD133 antigens; it has the potential to be a universal cancer vaccine because CD133 is widely expressed on CSCs from a majority of cancers. Data from this small study demonstrated that ICT-109 had a statistically ability to discriminate between cancerous and non-cancerous samples, suggesting the potential to detect pancreatic and lung cancer in plasma and serum study sets. The DIAAD (differential immunization for an! tigen and antibody discovery) platform it acquired from Molecular Discoveries utilizes immunological tolerization to accelerate the discovery of the molecular differences between diseased cells and their normal counterparts. The monoclonal antibodies produced by DIAAD provide the basis for the discovery and development of its potential diagnostic and therapeutic products.

The Company competes with Dendreon, Oncothyreon, Galena, Bavarian Nordic and Immunovaccine, Northwest Biotherapeutics, Prima Biomed, DCPrime, Roche/Genentech, Seattle Genetics, Bristol-Myers Squibb and Immunogen.

Advisors' Opinion:

• [By Wallace Witkowski]

  Shares of ImmunoCellular (IMUC) �jumped after the drug developer said data on a mid-stage brain cancer drug study were looking encouraging.

• [By Monica Gerson]

  ImmunoCellular Therapeutics (NYSE: IMUC) dropped 11.05% to $1.3699. ImmunoCellular's trailing-twelve-month ROE is -59.80%.

  Posted-In: market losersNews Movers & Shakers Intraday Update Markets

• [By Smith On Stocks]

  Using my assumptions, the common of Agenus might be worth about $7.00 per share in early 2014 based on the royalties from the Glaxo vaccines and the net operating loss carry forward even if every other asset in the company were valued at zero. However, there may be substantial value in Agenus' internal vaccine programs in recurrent and newly diagnosed glioblastoma and the genital herpes vaccine. Based on a comparison to peer companies like Northwest Biotherapeutics (NWBO) and ImmunoCellular Therapeutics (IMUC), I believe that the internal programs at Agenus currently may be worth $150 million or $4.45 per share. Adding this to the value of the MAGE A-3 vaccine could produce a stock price of $11.00 in early 2014.

Top 10 Medical Companies For 2014: Alere Inc (ALR)

Alere Inc., incorporated on May 11, 2001, is a provider of point-of-care diagnostics and services. The Company's products and services help healthcare practitioners make treatment decisions and improve outcomes for individuals living with chronic disease. The Company's portfolio also includes a range of health information solutions that access to critical health data, provide clinical decision support, and facilitate performance reporting and analysis. The Company�� segment includes professional diagnostics, health information solutions and consumer diagnostics. The Company distributes its professional diagnostic products to hospitals, reference laboratories, physician offices and other point-of-care settings through an worldwide distribution networks. In February 2013, the Company acquired Epocal, Inc.

Professional Diagnostics

Professional diagnostics are generally designed to assist medical professionals in both preventative and interventional medicine, and include testing and monitoring performed in hospitals, laboratories and doctors' offices and, increasingly, patient self-testing, which the Company defines as testing or monitoring performed at home under the supervision of a medical professional. Professional diagnostic products provide for qualitative or quantitative analysis of patient samples for evidence of a specific medical condition, disease state or toxicological state or to measure response to therapy. The point-of-care market for rapid diagnostic products includes all areas where a patient is assessed or diagnosed, including hospitals, laboratories, physician offices, specialized mobile clinics, emergency rooms, rapid-response laboratories and patient health screening locations.

The Company's Alere Cholestech LDX System is a point-of-care monitor of blood cholesterol and related lipids which is used to test patients at risk of, or suffering from, heart disease and related conditions. The Alere Cholestech LDX System makes it possible to provide ! a complete lipid profile with tests for total cholesterol, high-density lipoprotein cholesterol (HDL) and low-density lipoprotein cholesterol (LDL), triglycerides, and glucose. The Company's Alere INRatio System is an easy-to-use, hand-held blood coagulation monitoring system for use by patients and healthcare professionals in the management of warfarin, a commonly prescribed medication used to prevent blood clots. The Company also offers the epoc Blood Analysis System for bloods gas, electrolyte and metabolite testing, which is manufactured by its recently acquired Epocal division. The epoc (enterprise point-of-care) platform is a point-of-care analysis system which provides Wireless bedside blood gas, electrolyte and metabolite measurement testing solutions and complements the Company's Alere Triage products in cardiology and emergency room settings.

The Company develops and markets a range of point-of-care tests for influenza A/B, RSV, strep throat, pneumonia, C. difficile, infectious mononucleosis, HIV, herpes simplex virus (HSV-2), hepatitis C (HCV), hepatitis B (HBV), malaria, lyme disease, Chlamydia, H. pylori, rubella and other infectious diseases. The Company's tests for infectious disease are sold under brand names that include Alere, Alere Determine, Acceava, BinaxNOW, Clearview, DoubleCheckGold, Panbio, SD, TECHLAB and Alere TestPack. In addition to point-of-care products, the Company also offers a line of indirect fluorescent antibody, or IFA, assays for over 20 viral, bacterial and autoimmune diseases, a full line of serology diagnostic products covering a range of disease categories and over 50 enzyme-linked immunosorbent assay (ELISA), tests for a range of infectious and autoimmune diseases, as well as a full line of automated instrumentation for processing ELISA tests.

The Company offers laboratory-based testing services throughout Europe under the name Alere Toxicology, formerly Concateno, and in the United States under the names Alere Toxicology Services, or! Alere To! xicology, and Redwood Toxicology Laboratory, or Redwood. The Company offers point-of-care diabetes products, including its Afinion Analyzer System and its NycoCard System. The Company's Alere Connect products include HealthPAL and HealthCOM.

Health Information Solutions

The Company's health information solutions are designed to provide physicians with actionable data that allows them to make more decisions in real time, deliver quality care, and put the individuals they treat on a pathway to better health. The Company offers a range of software-based analytics, clinical decision support tools, and accountable cares programs that enable healthcare providers to initiate earlier interventions, personalize treatment plans, lower costs by reducing hospital readmissions, and measure improvements in outcomes at both a patient and population level. With this range of scalable solutions, the Company is able to support healthcare practitioners in the transition to accountable care, as well as in meeting the new pay-for-performance guidelines set by the Centers for Medicare & Medicaid Services (CMS).

The Company's Women's and Children's Health division delivers a range of obstetrical care services that range from risk assessments focused on identifying women who may experience pregnancy complications to a neonatal program that supports early infant care management. The Company offers home-based obstetrical monitoring for pregnant women with medical or pregnancy-related problems that could puts their health or the health of their babies at risk. The Company also delivers telephonic and home-based nursing services that support improved clinical outcomes. The Company offers a suite of integrated wellness programs and resources that is designed to reduce participant health risks and healthcare-related costs. The Company's wellness programs include screening for risk factors associated with chronic disease, particularly tobacco use, poor nutrition, physical inactivity, and chron! ic stress! .

The Company offers services designed to support anticoagulation management for patients who takes warfarin to control their risk for stroke and clotting disorders. Alere Home Monitoring, the Company's patient self-testing business, assists patients in acquiring home INR monitors and with insurance coverage determinations and provides physicians with a comprehensive model that allows them to incorporate patient self-testing into their practices.

Consumer Diagnostics

The Company's consumer diagnostic products consist of the Company's First Check brand of over-the-counter drug tests for at-home testing for up to seven illicit drugs and five prescription drugs, as well as First Check brand over-the-counter tests for cholesterol monitoring. The Company also sells Balance Activ Vaginal Gel directly to consumers and healthcare professionals for the treatment of bacterial vaginosis without antibiotics.

The Company competes with Abbott, Siemens, Beckman Coulter, Johnson & Johnson, Roche, Abaxis Medical Diagnostics, International Technidyne Corporation, INOVA Diagnostics, DiaSorin, Diamedx and Qiagen.

Advisors' Opinion:

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Alere (NYSE: ALR  ) , whose recent revenue and earnings are plotted below.

Top 10 Medical Companies For 2014: Five Prime Therapeutics Inc (FPRX)

Five Prime Therapeutics, Inc., incorporated on December 20, 2001, is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. Protein therapeutics is antibodies or drugs developed from extracellular proteins or protein fragments that block disease processes, including cancer and inflammatory diseases. The Company�� advanced product candidates include FP-1039/GSK3052230 (FP-1039), FPA008 and FPA144. FP-1039 is a protein therapeutic that traps and neutralizes cancer-promoting fibroblast growth factors (FGFs), involved in cancer cell proliferation and new blood vessel formation. FPA008 is an antibody that inhibits colony stimulating factor-1 receptor (CSF1R), and is being developed to treat patients with inflammatory diseases, including rheumatoid arthritis (RA). FPA144 is an antibody that inhibits FGF receptor 2b (FGFR2b), and is being developed to treat patients with gastric cancer and potentially other solid tumors.

FP-1039

FP-1039 is a protein therapeutic, which includes the extracellular part of FGFR1. FP-1039 acts as an inhibitor of FGFs, because the FGFR1 portion of the molecule binds to FGFs and prevents them from binding to FGFR1 on tumor and blood vessel cells. Because FGF proteins circulating in the blood are called ligands, FP-1039 is called a ligand trap. FP-1039 also includes a portion of an antibody called the Fc region. In preclinical testing, it observed inhibition of tumor growth with single-agent FP-1039, particularly in tumors withFGFR1 gene amplification, including squamous NSCLC and SCLC.

FPA008

FPA008 is an antibody that inhibits CSF1R and is being developed to treat patients with RA. FPA008 also has the potential to treat patients with other inflammatory diseases, including lupus nephritis, psoriatic arthritis, ankylosing spondylitis, fibrosis, inflammatory bowel disease and multiple sclerosis. These are chronic, incurable disorders with serious medical complications and disability for ! which better therapies with novel mechanisms of action are needed. FPA008 is an anti-CSF1R antibody, which it designed to block the ability of IL-34 and CSF1 to bind to and activate CSF1R. FPA008 reduces the numbers and activity of monocytes and macrophages that cause disease, and prevents the production and release of inflammatory factors. The Company and others has demonstrated that both IL-34 and CSF1 are present at increased levels in the inflamed joints of patients with RA.

FPA144

FPA144 is a monoclonal antibody directed against a form of FGFR2, or FGFR2b. When the FGFR2 gene is amplified by cancer cells, the FGFR2b protein is expressed at abnormally high levels on the tumor�� surface. This occurs in some patients with gastric and lower esophageal cancers. The tumor cells that have too much FGFR2b protein on their surface can be identified by special staining tests performed on the tumor. Because FGFR2b is the target for FPA144, patients��tumors can be screened for this protein, helping to identify the patients most likely to respond to FPA144 treatment.

Advisors' Opinion:

• [By Monica Gerson]

  Breaking news

  Alcoa (NYSE: AA) is investing US$13 million to expand its wheel manufacturing plant in Europe, to meet growing demand for its lightweight, durable, low-maintenance aluminum truck wheels. To read the full news, click here. L & L Energy (NASDAQ: LLEN) announced today that its Special Independent Committee has appointed Mr. Nicholas Chen, Managing Partner at Pamir Law Group, to replace Mr. Mark Bartlett. To read the full news, click here. Five Prime Therapeutics (NASDAQ: FPRX) and Bristol-Myers Squibb (NYSE: BMY) announced today that they have signed a collaboration agreement for the discovery, development and commercialization of immuno-oncology therapies directed toward targets identified in two undisclosed immune checkpoint pathways using Five Prime's proprietary target discovery platform. To read the full news, click here. First Solar (NASDAQ: FSLR) on Sunday announced the completion of the 1.3MW(DC) solar photovoltaic (PV) power plant at Kitakyushu-shi. Powered by First Solar FS Series 3 Black PV modules, the plant will generate approximately 1,400 MWh of clean and safe solar electricity per year. To read the full news, click here.

  Posted-In: Credit Suisse US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets

• [By Monica Gerson]

  Five Prime Therapeutics, Inc. (NASDAQ: FPRX) shares dropped 1.13% to $22.68 in pre-market trading after the company priced 3.41 million share offering at $22.00 per share.

Top 10 Medical Companies For 2014: Redhill Biopharma Ltd (RDHL)

Redhill Biopharma Ltd. is an Israel-based biopharmaceutical company. The Company is focused on the development and acquisition of therapeutic candidates. The Company�� pipeline consists of six late clinical development therapeutic candidates, two of which have completed bioequivalence clinical trials subject to review and approval by the United States Food and Drug Administration and, in some cases, regulatory authorities in other countries. The Company�� six clinical stage therapeutic candidates include RHB-101, RHB-102, RHB-103, RHB-104, RHB-105 and RHB-106.

RHB-101

RHB-101 is a treatment of hypertension, heart failure and left ventricular dysfunction (following myocardial infraction) by means of controlled release of an active ingredient known as carvedilol, which is designed to be administered to patients on a once-daily basis. RHB-101 is based on a patented technology for the controlled release of drugs administered orally.

RHB-102

RHB-102 is a once-daily controlled release oral formulation of ondansetron. RHB-102 utilizes a technology called CDT that uses salts to provide a controlled release of ondansetron.

RHB-103

RHB-103 is an oral thin film formulation of rizatriptan intended for the treatment of acute migraine headaches. Migraine is a neurovascular disorder (related to nerves and blood vessels) characterized by recurrent headaches in one side or both sides of the head.

The product is based on a technology called VersaFilm.

RHB-104

RHB-104 is an antibiotic combination therapy for the treatment of Crohn's disease (with a PIII clinical study underway), as well as Multiple Sclerosis (with an ongoing PIIa clinical study) and Rheumatoid Arthritis. RHB-104 is a combination of clarithromycin, clofazimine and rifabutin, three generic antibiotic ingredients, in a single capsule.

RHB-105

RHB-105, an antibiotics and proton pump inhibitor drug targeting Helico! bacter Pylori infection. RHB-105 is a combination of three approved drug products omeprazole, which is a proton pump inhibitor (the natural body pump that produces the gastric acids used for digesting the food in the stomach), and amoxicillin and rifabutin which are antibiotics. Chronic infection with Helicobacter pylori irritates the mucosal lining of the stomach and small intestine.

RHB-106

RHB-106, is a tablet for the preparation and cleansing of the gastrointestinal tract prior to the performance of abdominal procedures. Its abdominal procedures include diagnostic tests, such as colonoscopy, barium enema or virtual colonoscopy, as well as surgical interventions, such as laparotomy.

The company competes with GlaxoSmithKline, Sanofi-Aventis Groupe, Hoffman-La Roche Ltd, Merck and Co., Inc, Ferring Pharmaceuticals and Salix Pharmaceuticals Inc.

Advisors' Opinion:

• [By Monica Gerson]

  Breaking news

  Vitran Corporation (NASDAQ: VTNC) announced today that it has entered into a definitive arrangement agreement with TransForce pursuant to which TransForce has agreed to acquire all of the outstanding common shares of Vitran not already owned by TransForce for US$6.50 in cash per share, in accordance with TransForce's prior proposal. To read the full news, click here. ReneSola (NYSE: SOL) today announced it signed a Memorandum of Intent (MOI) to sell three utility-scale projects in Western China, with a total capacity of 60MW, to Jiangsu Akcome Solar Science & Technology Co on December 30, 2013. To read the full news, click here. Cooper Tire & Rubber Company (NYSE: CTB) today announced it has terminated the merger agreement with Apollo Tyres (NSE:ApolloTYRE). To read the full news, click here. RedHill Biopharma (NASDAQ: RDHL) today announced that it has entered into a definitive agreement with leading healthcare investor OrbiMed Israel Partners Limited Partnership, an affiliate of OrbiMed Advisors LLC, for the sale of RedHill's American Depository Shares and warrants in a private placement transactionor a total sum of $6.0 million. To read the full news, click here.

  Posted-In: Guggenheim US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets

Top 10 Medical Companies For 2014: MiMedx Group Inc (MDXG)

MiMedx Group, Inc. (MiMedx), incorporated on February 28, 2008, is an integrated developer, manufacturer and marketer of regenerative biomaterial products processed from human amniotic membrane. The Company�� biomaterial platform technologies include the device technologies HydroFix and CollaFix, and tissue technologies, AmnioFix and EpiFix. Its tissue technologies are processed from human amniotic membrane that is derived from the donated placentas. Through the Company�� donor program, mothers delivering full-term caesarian births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. MiMedx processes the human amniotic membrane utilizing its Purion Process to produce a manipulated implant for homologous use. MiMedx is the supplier of amniotic tissue, having supplied over 100,000 implants to distributors and other equipment manufacturers (OEMs) for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

The Company has three platform technologies. Its largest addressable market is in chronic wound care consisting of diabetic, venous and pressure ulcers. On January 5, 2011, the Company acquired all of the outstanding equity interests in Surgical Biologics, LLC. Located in Kennesaw, Georgia, Surgical Biologics develops allografts and other products processed from human amniotic membrane that can be used for a range of medical applications, including ocular surface repair, gum repair, wound care, nerve and tendon repair, spine repair, burn treatment, and many other types of procedures that require the repair of a patient�� integumental (native) tissue. Surgical Biologics has developed a specialized process for the processing of amniotic membrane to produce a manipulated allograft for homologous use.

AmnioFix and EpiFix

MiMedx is the supplier of allografts processed from amniotic tissue, having supplied over 70,000 allografts to date for application in the Ophthalm! ic, Orthopedic, Dental, Spinal and Wound Care segments of healthcare. Its amnion products, AmnioFix and EpiFix, are processed from human tissue. The AmnioFix and EpiFix allografts can be used for a range of procedures, including ocular surface repair, gingival recession repair, wound care, burns, and many other types of procedures for the repair of a patient�� integumental (native) tissue. Its AmnioFix technology also is used as a graft to reduce the amount of scar tissue formation, provide a local anti-inflammatory and help with the soft tissue healing of the area. EpiFix offers a range of wound healing and wound care options. Much of the clinical usage of EpiFix has been for wound care patients suffering from diabetic ulcers, pressure ulcers, vein circulation ulcers, or artery circulation ulcers.

CollaFix

The Company�� CollaFix technology combines a means of creating fibers from soluble collagen and a specialized cross-linking process. MiMedx utilizes two separate cross-linking technologies for various applications. Initial laboratory and animal testing shows that the cross-linked collagen fibers produce a biocompatible, and durable construct that can be transformed into surgical meshes intended to treat a number of orthopedic soft-tissue trauma and disease disorders.

HydroFix

The Company licenses rights to a polyvinyl alcohol (PVA) polymer, which is a water-based biomaterial that can be manufactured with a range of mechanical properties, including those that appear to mimic closely the mechanical and physical properties of natural, healthy human tissue. This hydrogel has been used in other orthopedic and general surgery device applications, and it has demonstrated biocompatibility and durability inside the human body. It has a similar version of the product for the European market called HydroFix Spine Shield. The device is classified as a post-surgical adhesion inhibiting barrier and is used in specific spine surgeries. In December the original! HydroFix! Spine Shield (for Anterior use Class IIb in Europe) was renamed to be HydroFix Anterior Shield.

The Company competes with W.L. Gore & Associates, Inc. and Stryker.

Advisors' Opinion:

• [By Sean Williams]

  What: Shares of MiMedx Group (NASDAQ: MDXG  ) , a manufacturer of patented regenerative biomaterial products (in essence, products designed to treat inflammation and help wounds heal), were eviscerated, falling as much as 70% at one point before recovering half of its losses after it announced the receipt of an untitled letter from the Food and Drug Administration alleging it does not possess the proper licensing to manufacture certain products.

• [By Bryan Murphy]

  It may not be as big as NuVasive, Inc. (NASDAQ:NUVA), and it might not be as sexy as MiMedx Group Inc. (NASDAQ:MDXG). But, Bacterin International Holdings Inc. (NYSEMKT:BONE) offers something to investors that MDXG and NUVA don't - can't - right now... a distinct opportunity for a lot of upside in a short amount of time.

• [By Rich Smith]

  MiMedx Group (NASDAQ: MDXG  ) ,�announced�Monday that results from a randomized controlled trial for its EpiFix wound-care allograft have been published in the International Wound Journal.�
  
  The clinical trial included patients with diabetic foot ulcers of at least four weeks' duration without infection, having adequate blood supply. Patients were broken into two groups, one receiving standard care alone, the other standard care plus EpiFix. After four and six weeks of treatment, the overall healing rate of patients treated with EpiFix was 77% and 92%, respectively, whereas standard care healed 0% and 8% of the wounds, respectively. The rate of healing with EpiFix exceeded that of standard treatment as well.
  
  According to the World Health Organization, diabetes will affect 366 million people worldwide -- up from 171 million in 2000.�Approximately 25% of diabetics will develop a chronic non-healing ulcer over their lifetime.�Diabetic foot ulcers�occur in 15% of all patients with diabetes and precede 84% of all lower leg amputations.
  
  EpiFix makes use of dehydrated human amniotic membrane to heal these ulcers. At room�temperature, EpiFix can have a shelf life of five years and retains the properties of the natural membrane.�Although there are similar, competing products on the market, the superior performance of�EpiFix compared with rival products (not yet proven by published studies) could help to make the company a market leader in the treatment of diabetic foot ulcers.

• [By Garrett Cook]

  MiMedx Group (NASDAQ: MDXG) shares were also up, gaining 12.10 percent to $7.04 after the company reported Q2 earnings of $0.00 per share on revenue of $25.60 million and raised its FY14 sales outlook.

Top 10 Wireless Telecom Stocks To Buy Right Now

Top 10 Wireless Telecom Stocks To Buy Right Now: Tim Participacoes SA (TIMP3)

TIM Participacoes SA (TIM) is a Brazil-based holding company engaged in the telecommunications segment. Through its wholly-owned subsidiaries, TIM Celular SA (TIM Celular) and Intelig Telecomunicacoes Ltda (Intelig), it provides telecommunication services throughout Brazil. TIM Celular and Intelig are active as Public Switched Telephony Network (PSTN) providers in the local and national and international long-distance modalities in all Brazilian states. Additionally, the Company provides multimedia communication services and personal mobile services, mobile data services and a third generation (3G) network, as well as international roaming agreements, multimedia messaging services, blackberry services and sale of related equipment. Advisors' Opinion:

• [By Jonathan Morgan]

  Telecom Italia SpA (TIT) jumped 6.2 percent to 65.6 euro cents. The phone company that was stripped of its investment-grade rating is seeking at least 9 billion euros for its controlling stake in Brazilian wireless carrier Tim Participacoes SA (TIMP3), according to a person with direct knowledge of the matter.

• [By Zahra Hankir]

  Brazils Ibovespa extended its weekly decline to 3.3 percent. Mobile carrier Tim Participacoes SA (TIMP3) sank after parent Telecom Italia SpA (TIT)s chief executive officer said its Brazilian assets are strategic, damping speculation the local unit will be sold.

source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/top-10-wireless-telecom-stocks-to-buy-right-now-4.html

Top 5 Solar Stocks For 2014

According to the Canadian Association of Petroleum Producers, or CAPP, Canadian oil production will more than double over the next two decades, fueled by steadily growing oil sands production and a rebound in conventional production.

But could the rise of alternative energy sources such as solar render expensive oil sands projects unprofitable within the next several years? Let's take a closer look.

CAPP's projections
CAPP forecasts total production to reach 6.7 million barrels per day in 2030, compared to roughly 3.2 million barrels per day last year. It expects oil sands output to account for a little over three-quarters of the expected 6.7 million barrels per day in 2030, or around 5.2 million barrels per day.

Conventional crude and condensate from western Canada will make up the remaining 1.4 million barrels per day, while eastern Canadian production is expected to account for the remaining 100,000 barrels per day, CAPP reckons.

That compares to last year's breakdown of 1.8 million barrels per day from the oil sands, 1.2 million barrels per day from western Canada, and 200,000 barrels per day from eastern Canada. CAPP's updated estimates are also slightly higher than last year's estimates, which forecast 5.02 million barrels per day from oil sands in 2030, 1.14 million barrels per day from western Canada, and 90,000 barrels per day from eastern Canada.

Top 10 Penny Companies To Watch In Right Now: Hanwha SolarOne Co. Ltd.(HSOL)

Hanwha Solarone Co., Ltd., an investment holding company, engages in the manufacture and sale of silicon ingots, silicon wafers, and PV cells and modules. The company also offers mono crystalline and multi crystalline silicon cells; and provides PV module processing services. It sells its products to solar power system integrators and distributors primarily in Germany, Italy, Australia, the United States, the Czech Republic, Spain, and China. The company was formerly known as Solarfun Power Holdings Co., Ltd. and changed its name to Hanwha SolarOne Co., Ltd. in December 2010. Hanwha Solarone Co., Ltd. was founded in 2004 and is based in Qidong, the People?s Republic of China.

Advisors' Opinion:

• [By Travis Hoium]

  What: Solar stocks are shooting higher again today as the strong run in 2013 continues. LDK Solar (NYSE: LDK  ) , Canadian Solar (NASDAQ: CSIQ  ) , Yingli Green Energy (NYSE: YGE  ) , Hanwha SolarOne (NASDAQ: HSOL  ) , and JinkoSolar (NYSE: JKS  ) led the way, gaining between 10% and 22% today.

Top 5 Solar Stocks For 2014: Real Goods Solar Inc.(RSOL)

Real Goods Solar, Inc. operates as a residential and commercial solar energy integrator primarily in California and Colorado. The company provides engineering, procurement, and construction services. It offers various turnkey solar energy services, including design, procurement, permitting, build-out, grid connection, financing referrals, and warranty and customer satisfaction services. The company installs residential and small commercial systems that range between 3 kilowatts and 1 megawatt output. It also engages in the retail sale of renewable energy products. The company was founded in 1978 and is based in Louisville, Colorado.

Advisors' Opinion:

• [By Bryan Murphy]

  If you were lucky enough to be in an American Community (OTCMKTS:ACYD) position anytime before October 8th, then congratulations - you're up big. Now get out. Instead, use freed-up that capital to take on a position in Real Goods Solar, Inc. (NASDAQ:RSOL), which looks like it's at the beginning of a good-sized rally.

• [By Bryan Murphy]

  Last Thursday when I suggested American Community (OTCMKTS:ACYD) was a stock that should be shed immediately, and replaced with a position in Real Goods Solar, Inc. (NASDAQ:RSOL), I didn't win a lot of friends. After all, ACYD was the market's newest darling, in the middle of a red-hot runup, while RSOL was "just another solar name" that happened to be lucky enough to stumble its way above a key support line. Well, I hate to be the one to day I told you so, but, I told you so. American Community shares are down 35% since then, while Real Goods Solar shares are up 36% in the meantime. Both stocks seem pretty well entrenched in their current trends too.

• [By Bryan Murphy]

  There's no denying that LDK Solar Co., Ltd (NYSE:LDK) has been a notable laggard this year compared to performances from First Solar, Inc. (NASDAQ:FSLR) and Real Goods Solar, Inc. (NASDAQ:RSOL). RSOL is up nearly 180% year-to-date, with a decent chunk of that gain unfurling in just the last couple of months. FSLR is up 25% for the year so far, though that more modest gain would have been much bigger had it not been for February's 24% plunge. Meanwhile, LDK shares are down 22% year-to-date, and have barely even blipped despite the fact that solar energy has become all the rage again in recent months.

Top 5 Solar Stocks For 2014: Canadian Solar Inc.(CSIQ)

Canadian Solar Inc. engages in the design, development, manufacture, and sale of solar power products in Canada and internationally. The company offers solar cell and solar module products that convert sunlight into electricity for various uses. Its products include a range of standard solar modules for use in a range of residential, commercial, and industrial solar power generation systems. The company also designs and produces specialty solar modules and products consisting of customized modules that its customers incorporate into their products, such as solar-powered bus stop lighting; and specialty products, such as portable solar home systems and solar-powered car battery chargers. In addition, it sells solar system kits, a package consisting of solar modules produced by it and third party supplied components, such as inverters, racking system, and other accessories, as well as implements solar power development projects. The company sells its products under the Canad ian Solar brand name. Canadian Solar Inc. offers its standard solar modules through a direct sales force and sales agents primarily to distributors, system integrators, and original equipment manufacturer customers, as well as to solar projects; and specialty solar modules and products to the automotive, telecommunications, and light-emitting diode lighting sectors. The company was founded in 2001 and is based in Kitchener, Canada.

Advisors' Opinion:

• [By James Brumley]

  Relative to its size, Canadian Solar (CSIQ) is the most overlooked of these solar stocks.

  Depending on the year in question, the company ranks anywhere from being in the top five to the top three suppliers in the world. And it supplies the whole world, with big, equitable demand from the United States, China, and Japan … three nations with lots of their own solar panel manufacturers, and a bent for protectionism. Canadian Solar simply muscles its way into key markets, generating sales growth of 27% in 2013.

Top 5 Solar Stocks For 2014: JinkoSolar Holding Company Limited(JKS)

JinkoSolar Holding Co., Ltd., together with its subsidiaries, engages in the manufacture and sale of solar power products in China and internationally. The company provides solar modules, silicon wafers and ingots, and solar cells, as well as processing services, including silicon wafer tolling services. It sells its products under the JinkoSolar brand name. The company?s customers include distributors, project developers, and system integrators. It trades its products under short-term contracts and by spot market sales. The company also produces accessory materials for solar power products, such as solar aluminum frame, solar junction box, aluminum materials windows, and other metal component parts. JinkoSolar Holding Co., Ltd. was founded in 2006 and is based in Shangrao, the People?s Republic of China.

Advisors' Opinion:

• [By Dan Caplinger]

  On the other hand, if you were looking to buy stocks, Monday turned out to be a great time to do so. For instance, in the solar arena, JinkoSolar (NYSE: JKS  ) and Trina Solar (NYSE: TSL  ) plunged Monday on feras of the impact of geopolitical tension on the solar business, even though Jinko had reported reasonably strong results earlier that day. Yet Monday, Trina and Jinko soared, with Trina's positive report confirming the health of the solar industry.

• [By Eric Volkman]

  JinkoSolar (NYSE: JKS  ) suffered a widened quarterly loss, as revealed in the release of its fiscal Q4 and 2012 results. For the quarter, revenue for the China-based solar specialist was the equivalent of $187 million, down from $192 million in the same period the previous year. Net loss widened over that time span, to $122 million, or $1.38 per share, from Q4 2011's red figure of $59 million, $0.65.

• [By Monica Gerson]

  Analysts are expecting JinkoSolar Holding Co (NYSE: JKS) to have earned $0.76 per share on revenue of $391.55 million in the second quarter. JinkoSolar shares gained 1.73% to $28.30 in after-hours trading.

• [By Monica Gerson]

  JinkoSolar Holding Co (NYSE: JKS) is projected to report its Q2 earnings at $0.76 per share on revenue of $391.55 million.

  Urban Outfitters (NASDAQ: URBN) is expected to post its Q2 earnings at $0.49 per share on revenue of $806.99 million.

Best Dividend Companies To Invest In Right Now

Best Dividend Companies To Invest In Right Now: Waste Management Inc.(WM)

Waste Management, Inc., through its subsidiaries, provides waste management services to residential, commercial, industrial, and municipal customers in North America. It offers collection, transfer, recycling, and disposal services. The company also owns, develops, and operates waste-to-energy and landfill gas-to-energy facilities in the United States. Its collection services involves in picking up and transporting waste and recyclable materials from where it was generated to a transfer station, material recovery facility, or disposal site; and recycling operations include collection and materials processing, plastics materials recycling, and commodities recycling. In addition, it provides recycling brokerage, which includes managing the marketing of recyclable materials for third parties; and electronic recycling services, such as collection, sorting, and disassembling of discarded computers, communications equipment, and other electronic equipment. Further, the company e ngages in renting and servicing portable restroom facilities to municipalities and commercial customers under the Port-o-Let name; and involves in landfill gas-to-energy operations comprising recovering and processing the methane gas produced naturally by landfills into a renewable energy source, as well as provides street and parking lot sweeping services. Additionally, it offers portable self-storage, fluorescent lamp recycling, and medical waste services for healthcare facilities, pharmacies, and individuals, as well as provides services on behalf of third parties to construct waste facilities. The company was formerly known as USA Waste Services, Inc. and changed its name to Waste Management, Inc. in 1998. Waste Management, Inc. was incorporated in 1987 and is based in Houston, Texas.

Advisors' Opinion:

• [By Tom Rojas and M! aria Armental var popups = dojo.query(".socialByline .popC"); ]

  Waste Management Inc.(WM) said its third-quarter earnings fell 7% as the trash hauler and recycler works to cut its corporate overhead costs amid tepid pricing.

• [By Damian Illia]

  During 2008, Republic Services and Allied Waste merged to create a strong company which could compete with number-one waste management company Waste Management Inc. (WM). It is true this industry has a rather constant nature, as trash volume increases with population growth, urban construction, industrial production and commercial activity. Still, the macroeconomic context during 2008 affected the recently-merged company, having to deal with lower waste volumes and intense price competition. Nevertheless, after this bumpy beginning, the company reached a good profitability. And, although it came to sustain average growth on both gross and operating margins, this tendency has recently decelerated with this margins underperforming in 2012 and 2013.

source from Top Stocks For 2015:http://www.topstocksblog.com/best-dividend-companies-to-invest-in-right-now-3.html

Top 10 Railroad Companies To Watch In Right Now

When�TransCanada� (NYSE: TRP  ) first announced its plan to construct the Keystone XL pipeline, I'm sure company executives never thought it would wind up as one of the most polarizing environmental symbols in recent memory. Nor could they have predicted that the approval process would take, well, forever.

The exceedingly long duration of that process has allowed the Keystone XL to grow from a large pipeline to a larger than life feedstock for environmental, political, and economic arguments, and even a conspiracy theory or two. Some have really taken to the notion, for example, that Warren Buffett has a hand in delaying the pipeline project in order to boost his railroad business. The theory is that Buffett is encouraging President Obama into stalling on his decision to approve or deny Keystone XL. If the President does deny Keystone XL, the thinking goes, that is only further proof of Buffett's hold on him. Some of us may think this is a ridiculous theory, but given the power of money in Washington, let's take a closer look anyway.

Top Beverage Stocks To Buy Right Now: S&P GSCI(GD)

General Dynamics Corporation, an aerospace and defense company, provides business aviation; combat vehicles, weapons systems, and munitions; military and commercial shipbuilding; and communications and information technology products and services worldwide. Its Aerospace group designs, manufactures, and outfits various large and mid-cabin business-jet aircraft; provides maintenance, repair work, fixed-based operations, and aircraft management services; and performs aircraft completions for aircraft. The company?s Combat Systems group offers tracked and wheeled military vehicles, weapons systems, and munitions. Its product lines include wheeled combat and tactical vehicles; battle tanks and infantry vehicles; munitions and propellant; rockets and gun systems; and axle and drivetrain components and aftermarket parts. This group also manufactures and supplies engineered axles, suspensions, and brakes for heavy-load vehicles for military and commercial customers. The company Advisors' Opinion:

• [By Rich Smith]

  The U.S. Department of Defense started the week slow Monday, awarding only five new contracts to its defense contractors, and those five worth less than $120 million in aggregate. Of these, the two largest awards went to publicly traded companies, specifically:

  BAE Systems' (NASDAQOTH: BAESY  ) San Diego Ship Repair subsidiary, which won a $38.6 million modification to a previously awarded contract to perform upgrades on the guided missile destroyer USS Benfold (DDG-65). BAE is expected to complete this work by August 2014. General Dynamics' (NYSE: GD  ) soon-to-be merged-out-of-existence Armament and Technical Products unit, which was awarded a $32.7 million firm fixed-price multi-year procurement contract for the production of MK82 Mod 0 Aegis gun and guided-missile directors and MK 200 Mod 0 Aegis director controllers to be incorporated into six Aegis Weapon System ship sets.

  The Aegis Weapon System, described by its maker, Lockheed Martin (NYSE: LMT  ) , as "the world's premier naval air defense system," consists of an integrated SPY-1 multi-function phased array radar system, integrated into a missile battery, and can be used for shipboard defense against everything from aircraft to conventional missiles to ballistic missiles.

• [By Rich Smith]

  According to the DSCA, contractors General Dynamics (NYSE: GD  ) , Boeing (NYSE: BA  ) , and Wyle Laboratories are in line to perform avionics software upgrades and engine component improvements and to sell ground support equipment, spare parts, technical documentation, and other "technical and logistics support services" to Kuwait for an estimated $200 million.

• [By Rich Smith]

  So what's really going on over there in Washington today? Is defense spending stalled, or will it rise again? And what does this mean for ultra-low-P/E-bearing stocks like Boeing (NYSE: BA  ) , Lockheed Martin� (NYSE: LMT  ) , Northrop Grumman� (NYSE: NOC  ) , and General Dynamics� (NYSE: GD  ) .

• [By Rich Smith]

  Don't look now, but General Dynamics (NYSE: GD  ) may be about to win another multimillion-dollar weapons contract.

  That's the upshot of a new report out of DefenseNews.com, which itself cites a report in Germany's Handelsblatt newspaper warning that Saudi Arabia is about to cancel a deal to pay Germany $6.5 billion to acquire 270 new Leopard main battle tanks. According to DefenseNews.com, the Saudis are considering giving the contract to General Dynamics, and buying that company's Abrams main battle tanks, instead.

Top 10 Railroad Companies To Watch In Right Now: LifeLock Inc (LOCK)

LifeLock, Inc., incorporated on April 12, 2005, is a provider of proactive identity theft protection services for consumers and identity risk assessment and fraud protection services for enterprises. It operates in two segments: consumer segment and an enterprise segment. In its consumer segment, the Company offer identity theft protection services to consumers on a monthly or annual subscription basis. In its enterprise segment, it offer identity risk assessment and fraud protection services to enterprise customers who pay the Company based on their monthly volume of transactions with it. It protects its consumer subscribers, whom it refers to as its members, by monitoring identity-related events, such as new account openings and credit-related applications. It also provides remediation services to its members in the event that an identity theft actually occurs. On March 14, 2012, the Company acquired ID Analytics, Inc. In December 2013, the Company announced that it has completed the acquisition of Lemon Inc.

Consumer Business

The Company protects its members by proactively monitoring identity-related events, such as new account openings and credit-related applications, which may present a risk of identity theft. If it detects that a member�� personally identifiable information is being used, the Company sends notifications and alerts, including proactive, near real-time, actionable alerts, to the member via text message, phone call, or e-mail through its LifeLock Identity Alert system that allows the member to confirm valid or unauthorized identity use.

Enterprise Business

The Company delivers on-demand identity risk assessment and authentication information about consumers to its enterprise customers in their daily transaction flows. Its enterprise customers utilize this information in real time to authenticate their customers, assess their risk profile, and enhance the enterprise�� decision making process on which to base account opening, le! nding, credit, and other risk-based decisions. By integrating its services into their business processes, its enterprise customers can reduce potential financial losses from identity fraud. Information generated from the transaction flow at its enterprise customers is transmitted back to its data repositories, which continually enhances the LifeLock ecosystem and helps strengthen the services the Company can provide to its customers in the future.

The Company competes with Experian, Equifax, TransUnion, Affinion, Early Warning Systems, Intersections and LexisNexis.

Advisors' Opinion:

• [By Jon C. Ogg]

  LifeLock Inc. (NYSE: LOCK) has only been public for about 15 months. It is a high beta stock, trading at 55-times expected trailing earnings and almost 48-times expected 2014 earnings. The driving force here is that identity theft and organized global fraud against consumers is forcing everyone to buy identity protection services. Target was the worst recent news on this front, but there are literally dozens of other companies who have had data breaches on their millions of customers. LifeLock shares hit a new high of $20.83 on Friday and closed up 1.6% at $20.41 on the day. This one is up about 150% from its IPO in late 2012.

• [By Jake L'Ecuyer]

  LifeLock (NYSE: LOCK) was also down, falling 15.33 percent to $10.99 after the company announced Friday that it had halted its mobile wallet service, shocking the street.

• [By Rick Aristotle Munarriz]

  AFP/Getty Images/Gabriel Bouys Companies can make brilliant moves, but there are also times when things don't work out quite as planned. From a luxury electric car maker ramping up its production to sandwich makers failing to make dough rise, here's a rundown of the week's smartest moves and biggest blunders in the business world. Tesla Motors (TSLA) -- Winner The Model S isn't cheap, but Tesla is selling enough of them to impress investors. Shares of the maker of plug-in electric vehicles raced to a new high after announcing that it delivered 6,892 cars in its latest quarter. Things will get even better in 2014 as Tesla expects to sell and deliver 35,000 vehicles. Tesla will need to ramp up its production -- currently, roughly 600 cars a week -- to closer to 1,000 Model S and new Model X cars by the end of the year. Conn's (CONN) -- Loser It isn't easy running a consumer electronics store these days. Shares of Conn's plunged 43 percent on Thursday after warning that its holiday quarter results will fall well short of its earlier expectations. If that seems like a significant drop for a mere miss, let's dive a little deeper. Conn's also warned that it's suffering from higher loan delinquencies than usual. Conn's provides in-house consumer credit on its appliances, furniture, mattresses, and consumer electronics, so revealing that 8.8 percent of its loan portfolio hasn't made a payment in more than 60 days is problematic. Conn's, which has stores in the Southwest, blames cold weather for disrupting payments, but things are never as simple as that. Conn's was holding up better than its peers that had imploded earlier this year on reports that the holidays weren't so jolly this time around. Now we know that Conn's is merely mortal, and that way too many of its customers last year aren't current on their payments. Candy Crush Saga -- Winner The company behind "Candy Crush Saga" filed to go public this week. Dublin-based King Digital Entertainment is hoping

Top 10 Railroad Companies To Watch In Right Now: Box Ships Inc.(TEU)

Box Ships Inc. owns and operates containerships. As of August 16, 2011, it operated a fleet of 7 containerships with a total carrying capacity of 33,237 twenty-foot equivalent units. The company was founded in 2010 and is based in Athens, Greece.

Advisors' Opinion:

• [By Monica Gerson]

  Box Ships (NYSE: TEU) shares fell 20.38% to reach a new 52-week low of $1.90 after the company priced 5 million units at $2.05 per unit.

  Toyota Motor (NYSE: TM) shares reached a new 52-week low of $104.90. Toyota shares have dropped 4.90% over the past 52 weeks, while the S&P 500 index has gained 17.50% in the same period.

• [By Eric Volkman]

  TearLab (NYSE: TEU  ) is looking to widen its capital base by more than $32 million in an underwritten public offering of its common stock. The company is floating 2.6 million shares at a price of $13.50 apiece. Additionally, the company's underwriters have been granted a 30-day purchase option for up to an additional 15% of the total number of shares to cover overallotments.

• [By Monica Gerson]

  Box Ships (NYSE: TEU) slipped 18.49% to $1.94 after the company priced 5 million units at $2.05 per unit.

  China Auto Logistic (NASDAQ: CALI) shares dropped 9.06% to $3.17 after the company announced 2013 results. China Auto Logistic posted its net income of $524,260, or $0.14 per share.

• [By ABN]

  TAL International Group (TAL) is one of the world's largest lessors of intermodal freight containers for the shipping business with 17 offices in 11 countries and approximately 230 third-party container depot facilities in 40 countries. TAL's fleet consists of approximately 1,238,000 containers and 2,031,000 twenty-foot equivalent units (TEU).

Top 10 Railroad Companies To Watch In Right Now: Education Realty Trust Inc. (EDR)

Education Realty Trust, Inc., a real estate investment trust (REIT), develops, acquires, owns, and manages student housing communities located near university campuses in the United States. It also provides third-party management services, including residence life and student development, marketing, leasing administration, strategic relationships, information systems, and accounting services for student housing communities owned by educational institutions and charitable foundations. In addition, the company offers third-party development consulting services, such as market analysis and evaluation of housing needs and options; co-operation with university in architectural design; negotiation of ground lease, development agreement, construction contract, architectural contract, and bond documents; oversight of architectural design process; co-ordination of governmental and university plan approvals; oversight of construction process; design, purchase, and installation of fu rniture; pre-opening marketing to students; and obtaining final approvals of construction. It provides its third-party development consulting services primarily to universities seeking to modernize their on-campus student housing communities, as well as to other third-party investors. As of December 31, 2009, the company owned 40 student housing communities located in 19 states containing 25,454 beds in 7,813 apartment units located near 35 universities. It also provided third-party management services for 20 student housing communities located in 9 states containing 10,186 beds in 3,272 apartment units at 16 universities. The company qualifies as a REIT for federal income tax purposes. As a REIT, it would not be subject to federal corporate income tax if it distributes at least 90% of its REIT taxable income to its stockholders. The company was founded in 1964 and is based in Memphis, Tennessee.

Advisors' Opinion:

• [By Monica Wolfe]

  Education Realty Trust (EDR)
  
  Over the past week two insiders made some buys. Both the CEO as well as the company�� CFO made these buys.

  Executive VP, CFO and Treasurer Randall Brown bought 5,500 shares at $9.04 per share. This cost him a total of $49,720. The price per share has increased 1.44% since then. Brown now holds on to 99,346 shares of company stock.

• [By Rich Duprey]

  College dorm room operator�Education Realty Trust (NYSE: EDR  ) announced today its second-quarter dividend of $0.11 per share, a 10% hike in the payout of $0.10 per share that it made last quarter.

Top 10 Railroad Companies To Watch In Right Now: Aberdeen Asset Management PLC (ABDNY)

Aberdeen Asset Management PLC is a global asset management company investing across the four main asset classes of equity, fixed income, property and alternative investment strategies. The Company operates in 23 countries. It has reorganized the Aberdeen Private Equity Fund, which is its private equity investment vehicle. The Company�� business is the management of financial assets for third parties. Its key clients include national and corporate pension funds, central banks and other investment institutions. It is a property asset manager in Europe and manages assets in Europe, Asia and North America. Effective February 20, 2014, Aberdeen Asset Management PLC acquired The Capitol Shopping Centre. In May 2014, the Company acquired Scottish Widows Investment Partnership's Infrastructure fund management business. Also completed acquisition of Scottish Widows Partnership Group Ltd and its related private equity and infrastructure fund management businesses from Lloyds Banking Group plc. Advisors' Opinion:

• [By John Udovich]

  The poorly conceived Scottish Independence vote has failed���something that could be good news for Scottish stocks like Royal Bank of Scotland Group plc (NYSE: RBS), Aberdeen Asset Management (OTCMKTS: ABDNY) and SSE PLC (OTCMKTS: SSEZY) that have well traded ADRs on US exchanges. To begin with, its worth mentioning the work done by Paul Marsh of London Business School and Scott Evans of Walbrook Economics where they identified 100 purely Scottish stocks currently listed in London and compared this with a parallel ��est of the UK��index over the last 60 years. They found that 拢1 invested in the Scotsie 100 in 1955 would have grown to 拢648 today (with dividends reinvested), a 5.7% increase in real (inflation-adjusted) terms. However, 拢1 invested in the rest of the UK would have grown to 拢1,168, a 6.8% increase.

Top 10 Railroad Companies To Watch In Right Now: Building Turbines Inc (BLDW)

Building Turbines Inc (BTI), incorporated on November 17, 1997, is engaged in the designing and manufacturing rooftop mounted wind turbines. The patented BTI�� design is ideal for commercial applications and creates reliable, cost-effective, clean and on-site renewable electricity. The Company offers a different, patented wind turbine product that can bring the dream of clean, affordable wind energy to a reality. The turbine is mounted on a steel frame, it has a low profile, low maintenance needs, and creates almost no noise or vibration.

The Company�� design possesses these exemplary and robust structural, mechanical and electrical characteristics that are particularly important when mounting a renewable energy system onto a building's roof. The turbine can help office buildings, schools, warehouses, distribution centers, airports, hotels, and a variety of other buildings offset electricity purchased from the grid by creating it on-site from the wind. The turbine creates reliable, cost-effective and clean renewable electricity with little building modification required.

Advisors' Opinion:

• [By Peter Graham]

  Small cap green stocks Essential Innovations Technology Corp (OTCBB: ESIV), Building Turbines Inc (OTCMKTS: BLDW) and Kleangas Energy Technologies Inc (OTCMKTS: KGET) have all been getting some attention lately in various investment newsletters ��either because they were sinking, because of paid promotions or a combination of both. However, there aren�� many green stocks out there that have actually produced some green for investors in the form of profits. With that in mind, here is a quick reality check about all three green small cap stocks to help you decide whether any have the potential for long-term success:

• [By Peter Graham]

  Small cap green stocks Building Turbines Inc (OTCMKTS: BLDW), Virtual Sourcing, Inc (OTCMKTS: PGCX) and Unseen Solar, Inc (OTCMKTS: PCWT) have been getting some attention lately in various investment newsletters in part because some ��reen�� is being paid out in the form of paid promotions or investor relation activity. Of course, there is nothing wrong with properly disclosed paid promotions, but you do need to remember that small cap stocks (especially those in new ��reen�� industries) already come with risk. With that in mind, here is a quick reality check about these three green small cap stocks and whether you can expect to see some green in the form of profits:

  Building Turbines Inc (OTCMKTS: BLDW) Has Secured a $5 Million Line of Credit

  Small cap Building Turbines Inc is focused on the design and manufacture of patented rooftop wind turbines as well as vertically integrating them into other renewable energy solutions to complete a total ��reen Energy Solution��for any urban environment. Building Turbines Inc�� subsidiary, Green City Planet, is also a premier provider of LED lighting and environmentally sound industrial solutions. On Friday, Building Turbines Inc fell 9.76% to $0.0370 for a market cap of $8.71 million plus BLDW is up 51% over the past year and down 87.2% since June 2011 according to Google Finance.

Top 10 Railroad Companies To Watch In Right Now: Carriage Services Inc (CSV)

Carriage Services, Inc. (Carriage), incorporated in December 1993, is a provider of death care services and merchandise in the United States. The Company operates in two business segments: funeral home operations and cemetery operations. As of December 31, 2011, the Company operated 159 funeral homes in 25 states and 33 cemeteries in 12 states. The Company provides funeral and cemetery services and products on both an at-need (time of death) and preneed (planned prior to death) basis. During the year ended December 31, 2011, Carriage completed two of the six acquisitions of funeral home businesses, one in Kentucky and the other in New York. In September 2011, the Company acquired Franklin & Downs Funeral Homes. In October 2011, the Company acquired Carman Funeral Home and Roberson Funeral Home, both in Northeast Kentucky. In February 2012, the Company acquired James J. Terry Funeral Home, Inc. On February 21, 2012, the Company acquired a funeral home business in Pennsylvania. In June 2012, the Company acquired Lawton Ritter Gray Funeral Home, Gray Funeral Home and Sunset Memorial Gardens in Lawton and Grandfield, Oklahoma. In December 2012, the Company acquired Cumby Family Funeral Service. In November 2013, Carriage Services Inc acquired Heritage Funeral Homes & Cremation Service.

Funeral Home Operations

The funeral homes offer a range of services (traditional burial and cremation) to meet a family�� death care needs, including consultation, the removal and preparation of remains, the sale of caskets and related funeral merchandise, the use of funeral home facilities for visitation and services, and transportation services. It provides burial and cremation services and sells related merchandise, such as caskets and urns. As of December 31, 2011, the Company operated 159 funeral homes in 25 states.

Cemetery Operations

The Company�� cemetery products and services include interment services, the rights to interment in cemetery sites (including gr! ave sites, mausoleum crypts and niches) and related cemetery merchandise, such as memorials and vaults. As of December 31, 2011, the Company operated 33 cemeteries in 12 states.

The Company competes with SCI, Stewart and StoneMor Partners L.P.

Advisors' Opinion:

• [By Dan Caplinger]

  The first thing to realize about StoneMor is that arcane and flexible accounting rules make it important to dig beneath its GAAP earnings. Growth throughout the industry has been substantial, as up-and-coming Carriage Services (NYSE: CSV  ) continued to stay on pace for double-digit sales growth as it rapidly expands its reach. Even well-established player Matthews International (NASDAQ: MATW  ) managed to grow revenue by nearly 14% in the quarter that ended in March, although its earnings fell slightly from the year-ago quarter. Still, StoneMor's sales haven't been able to rise as quickly as its peers, with its previous report including just a 6% gain in revenue.

• [By Rich Duprey]

  Death services specialist�Carriage Services (NYSE: CSV  ) announced today its third-quarter dividend of $0.025 per share, the same rate it's paid since 2011.